Dimethylamine

Dimethylamine

SCHEMBL6930952

CCn1c(N)nc2ccccc21.CNC

nearest known ligand 0.90

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.90
CYP2D6 P10635 1/20 0.90
HTT P42858 1/20 0.90
POLB P06746 3/20 0.68
TLR8 Q9NR97 3/20 0.64
CXCR4 P61073 1/20 0.62
KDM4E B2RXH2 3/20 0.56
ALDH1A1 P00352 3/20 0.56
HPGD P15428 2/20 0.56
TNF P01375 2/20 0.54
NOD2 Q9HC29 2/20 0.54
NOD1 Q9Y239 2/20 0.54
CXCL8 P10145 1/20 0.54
SOS1 Q07889 1/20 0.54
LMNA P02545 2/20 0.53
MAPT P10636 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
MAPK1 P28482 1/20 0.51
HSD17B10 Q99714 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimethylamine SCHEMBL6934118 0.98 CYP1A2 (0.87) CYP1A2CYP2D6HTTPOLBTLR8
SCHEMBL1992429 0.95 CYP1A2 (1.00) CYP1A2CYP2D6HTTPOLBTLR8
Diethylamine SCHEMBL8563676 0.90 CYP1A2 (0.84) CYP1A2CYP2D6HTTPOLBTLR8
SCHEMBL1520381 0.81 POLB (1.00) CYP1A2CYP2D6HTTPOLBTLR8
SCHEMBL5461912 0.80 POLB (0.69) CYP1A2CYP2D6HTTPOLBTLR8
SCHEMBL6199065 0.80 CXCR4 (0.85) CYP1A2CYP2D6HTTPOLBTLR8
SCHEMBL6694492 0.78 HTT (0.70) CYP1A2CYP2D6HTTPOLBTLR8
SCHEMBL2343059 0.78 TLR8 (1.00) CYP1A2CYP2D6HTTPOLBTLR8
SCHEMBL1170110 0.77 TLR8 (1.00) CYP1A2CYP2D6HTTPOLBTLR8
SCHEMBL6196399 0.77 CXCR4 (1.00) CYP1A2CYP2D6HTTPOLBTLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6660870-B1 Serotonergic compounds which possess agonist activity at 5-HT2 receptors effectively lower and control normal and elevated IOP and are useful for treating glaucoma ALCON, INC. (CH) 2003-12-09 US disclosed